Hybrid Coronary Revascularization for the Treatment of Multivessel Coronary Artery Disease: A Multicenter Observational Study

详细信息    查看全文

• 作者：John D. Puskas ; MD^a ; ^b ; ^{john.puskas@mountsinai.org" class="auth_mail" title="E-mail the corresponding author} ; Michael E. Halkos ; MD^c ; Joseph J. DeRose ; MD^d ; Emilia Bagiella ; PhD^e ; Marissa A. Miller ; DMV ; MPH^f ; Jessica Overbey ; MS^e ; Johannes Bonatti ; MD^g ; V.S. Srinivas ; MD^d ; Mark Vesely ; MD^h ; Francis Sutter ; MDⁱ ; Janine Lynch ; MPH^j ; Katherine Kirkwood ; MS^e ; Timothy A. Shapiro ; MDⁱ ; Konstantinos D. Boudoulas ; MD^j ; Juan Crestanello ; MD^j ; Thomas Gehrig ; MD^k ; Peter Smith ; MD^k ; Michael Ragosta ; MD^l ; Steven J. Hoff ; MD^m ; David Zhao ; MDⁿ ; Annetine C. Gelijns ; PhD^e ; Wilson Y. Szeto ; MD^o ; Giora Weisz ; MD^p ; Michael Argenziano ; MD^p ; Thomas Vassiliades ; MD^c ; ^q ; Henry Liberman ; MD^c ; William Matthai ; MD^o ; Deborah D. Ascheim ; MD^a ; ^e
• 刊名：Journal of the American College of Cardiology
• 出版年：2016
• 出版时间：26 July 2016
• 年：2016
• 卷：68
• 期：4
• 页码：356-365
• 全文大小：572 K

文摘

Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non–left anterior descending vessels. HCR is increasingly used to treat multivessel coronary artery disease that includes stenoses in the proximal left anterior descending artery and at least 1 other vessel, but its effectiveness has not been rigorously evaluated.

d="absSec_2">Objectives

d="abspara0015">This National Institutes of Health–funded, multicenter, observational study was conducted to explore the characteristics and outcomes of patients undergoing clinically indicated HCR and multivessel PCI for hybrid-eligible coronary artery disease, to inform the design of a confirmatory comparative effectiveness trial.

d="absSec_3">Methods

d="abspara0020">Over 18 months, 200 HCR and 98 multivessel PCI patients were enrolled at 11 sites. The primary outcome was major adverse cardiac and cerebrovascular events (MACCE) (i.e., death, stroke, myocardial infarction, repeat revascularization) within 12 months post-intervention. Cox proportional hazards models were used to model time to first MACCE event. Propensity scores were used to balance the groups.

d="absSec_4">Results

d="abspara0025">Mean age was 64.2 ± 11.5 years, 25.5% of patients were female, 38.6% were diabetic, and 4.7% had previous stroke. Thirty-eight percent had 3-vessel coronary artery disease, and the mean SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score was 19.7 ± 9.6. Adjusted for baseline risk, MACCE rates were similar between groups within 12 months post-intervention (hazard ratio [HR]: 1.063; p = 0.80) and during a median 17.6 months of follow-up (HR: 0.868; p = 0.53).

d="absSec_5">Conclusions

d="abspara0030">These observational data from this first multicenter study of HCR suggest that there is no significant difference in MACCE rates over 12 months between patients treated with multivessel PCI or HCR, an emerging modality. A randomized trial with long-term outcomes is needed to definitively compare the effectiveness of these 2 revascularization strategies. (Hybrid Revascularization Observational Study; d="intref0010" class="interref" data-locatorType="https" data-locatorKey="//www.clinicaltrials.gov/ct2/show/NCT01121263?term=NCT01121263&rank=1">NCT01121263)